| http://purl.uniprot.org/citations/23690342 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/23690342 | http://www.w3.org/2000/01/rdf-schema#comment | "We sought to identify novel pharmacogenetic markers associated with cardiovascular outcomes in patients with hypertension on antihypertensive therapy. We genotyped a 1:4 case:control cohort (n=1345) on the Illumina HumanCVD Beadchip from the INternational VErapamil SR-Trandolapril STudy (INVEST), where participants were randomized to a β-blocker strategy or a calcium channel blocker strategy. Genome-spanning single nucleotide polymorphism (SNP)×treatment interaction analyses of nonsynonymous SNPs were conducted in white and Hispanic race/ethnic groups. Top hits from whites were tested in Hispanics for consistency. A genetic risk score was constructed from the top 3 signals and tested in the Nordic Diltiazem study. SIGLEC12 rs16982743 and A1BG rs893184 had a significant interaction with treatment strategy for adverse cardiovascular outcomes (INVEST whites and Hispanics combined interaction P=0.0038 and 0.0036, respectively). A genetic risk score, including rs16982743, rs893184, and rs4525 in F5, was significantly associated with treatment-related adverse cardiovascular outcomes in whites and Hispanics from the INVEST study and in the Nordic Diltiazem study (meta-analysis interaction P=2.39×10(-5)). In patients with a genetic risk score of 0 or 1, calcium channel blocker treatment was associated with lower risk (odds ratio [95% confidence interval]=0.60 [0.42-0.86]), and in those with a genetic risk score of 2 to 3, calcium channel blocker treatment was associated with higher risk (odds ratio [95% confidence interval]=1.31 [1.08-1.59]). These results suggest that cardiovascular outcomes may differ based on SIGLEC12, A1BG, F5 genotypes, and antihypertensive treatment strategy. These specific genetic associations and our risk score provide insight into a potential approach to personalized antihypertensive treatment selection."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.org/dc/terms/identifier | "doi:10.1161/hypertensionaha.111.00823"xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "Gong Y."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "Padmanabhan S."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "Johnson J.A."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "Melander O."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "Dominiczak A.F."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "Langaee T.Y."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "Pepine C.J."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "Cooper-Dehoff R.M."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "McDonough C.W."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/author | "Burkley B."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/date | "2013"xsd:gYear |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/name | "Hypertension"xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/pages | "48-54"xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/title | "Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes."xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://purl.uniprot.org/core/volume | "62"xsd:string |
| http://purl.uniprot.org/citations/23690342 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/23690342 |
| http://purl.uniprot.org/citations/23690342 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/23690342 |
| http://purl.uniprot.org/uniprot/#_Q1L610-mappedCitation-23690342 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/23690342 |
| http://purl.uniprot.org/uniprot/#_A0A4V1DVZ0-mappedCitation-23690342 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/23690342 |
| http://purl.uniprot.org/uniprot/#_A0A4P8D7E0-mappedCitation-23690342 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/23690342 |
| http://purl.uniprot.org/uniprot/#_A0A4P8D7E7-mappedCitation-23690342 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/23690342 |
| http://purl.uniprot.org/uniprot/#_B4DU26-mappedCitation-23690342 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/23690342 |